Acute visual loss after ipilimumab treatment for metastatic melanoma

BACKGROUND: Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune related adverse events (IrAEs). CASE PRESENTATION: Here we describe a patient treated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Melissa A., Guld, Kelly, Galetta, Steven, Walsh, Ryan D., Kharlip, Julia, Tamhankar, Madhura, McGettigan, Suzanne, Schuchter, Lynn M., Fecher, Leslie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067900/
https://www.ncbi.nlm.nih.gov/pubmed/27777775
http://dx.doi.org/10.1186/s40425-016-0170-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067900/
https://www.ncbi.nlm.nih.gov/pubmed/27777775
http://dx.doi.org/10.1186/s40425-016-0170-9

Ejemplares similares